Mobile

Phase II trial of oral vinorelbine in combination with capecitabine as first line therapy in women with previously untreated HER2 negative metastatic breast cancer

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-000753-30

Femme Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the Overall Response Rate (ORR) of oral vinorelbine (Navelbine Oral) in combination with capecitabine (Xeloda) for HER2 negative patients.

Critère d'inclusion

  • Treatment in women with previously untreated HER2 negative metastatic breast cancer

Liens